Topics:

(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.

There is a myth circulating in the blogosphere—usually among the most extreme critics of our profession—that there exists some monolithic entity called “Psychiatry” (with a capital “P”).

The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?

Are you letting meaningless details squander your mental currency in rheumatology practice? The author points out how to recapture energy stolen by mere paperwork that should be used on your real job: Patient care.

Identifying patients who are likely to relapse despite continued, maintenance cognitive therapy can help optimize management of MDD and also help ensure efficient use of healthcare resources.

A 2-year study found a threefold increased risk of cardiovascular disease in older patients with major depression.

Nonsmokers who inhaled vapor from electronic cigarettes had diminished cough reflex after a single exposure, a new study found.

Several new studies feature developments in remyelination in MS. Oligodendrocyte precursor cells may be a promising target for MS treatments, and microRNA expression are perhaps an attractive MS biomarker.

With the advent and expansion of social media, we are seeing an increase in the phenomenon of mass humiliation. In this Q&A, we learn what surprised the author of a book on public shaming.

Pages

Subscribe to Psychiatric Times RSS

By clicking Accept, you agree to become a member of the UBM Medica Community.